The management of type 2 diabetes (T2D) has advanced dramatically over the past decade. While older injectable treatments such as exenatide, liraglutide, and basal insulin have served as mainstays of therapy, newer medications like Mounjaro (tirzepatide) have changed the landscape of T2D care. The Mounjaro KwikPen 2.5 mg starting dose of Mounjaro is now commonly recommended for treatment...